新肿瘤标志物及联合检测诊断子宫内膜癌的研究进展

子宫内膜癌患者早期诊断率低，目前仍缺乏敏感而特异的血清学标记物。已有学者研究血清肿瘤标志物CA125、人附睾分泌蛋白4（HE4）、甲壳质酶蛋白40(YKL-40)、periostin(PN)及血清细胞角蛋白片段抗原21-1(CYFRA21-1)在子宫内膜癌诊断中分别作为单项肿瘤标志物的应用，并且与传统肿瘤标志物CA125进行比较。近年来，CA125分别与HE4、YKL-40、CYFRA21-1、PN的联合检测在提高子宫内膜癌诊断的阳性率方面已进一步成为研究热点。新型肿瘤标志物与CA125的比较性研究及CA125与四种新型肿瘤标志物的联合检测研究得出:HE4、YKL-40、CYFRA21-1诊断子宫内膜癌的敏感度、特异度、准确度均高于血清CA125，PN敏感度低于CA125，联合检测诊断子宫内膜癌的敏感度、特异度、准确度均高于单项检测，有助于子宫内膜癌诊断、治疗及预后评估。

Progress on the new tumor markers and combined detection in the diagnosis of endome-trial carcinoma

The prognosis of endometrial carcinoma is poor partly due to the lackness of the sensitive and special ser-um markers.Many experts have demonstrated that carbohydrate antigen 125(CA125),serum human epididymal secre-tory protein 4(HE4),human cartilage glycoprotein -39(YKL -40),periostin(PN)and cytokeratin -19 -fragment (CYFRA21 -1)can be used as serum makers comparing with traditional CA125 in endometrial carcinoma.The sen-sitivity,specificity,accuracy of HE4,YKL -40,CYFRA21 -1 are better than CA125 while the sensitivity of PN is in-ferior to CA125.The accuracy of the combined detection is better than the single one,which is helpful to the diagno-sis,treatment and prognosis of endometrial carcinoma.